{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:41:33Z","timestamp":1781012493431,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Squamous cell carcinoma (SCC) and malignant pleural mesothelioma (MPM) are thoracic malignancies with very poor prognosis and limited treatment options. It is an established fact that most of the solid tumors have overexpression of EPHA2 receptor tyrosine kinase. EPHA2 is known to exhibit opposing roles towards cancer progression. It functions in inhibiting cancer survival and migration via a ligand and tyrosine kinase dependent signaling (Y772). Whereas it is known to promote tumor progression and cell migration through a ligand-independent signaling (S897). We analyzed the expression profile and mutational status of the ephrin receptor A2 (<jats:italic>EPHA2<\/jats:italic>) in SCC and MPM cell lines and primary patient specimens. The EPHA2 receptor was found to be either overexpressed, mutated or amplified in SCC and MPM. In particular, the <jats:italic>EPHA2<\/jats:italic> mutants A859D and T647M were interesting to explore, A859D Y772 dead mutant exhibited lower levels of phosphorylation at Y772 compared to T647M mutant. Molecular Dynamics simulations studies suggested that differential changes in conformation might form the structural basis for differences in the level of EPHA2 activation. Consequently, A859D mutant cells exhibited increased proliferation as well as cell migration compared to controls and T647M mutant. Kinomics analysis demonstrated that the STAT3 and PDGF pathways were upregulated whereas signaling through CBL was suppressed. Considered together, the present work has uncovered the oncogenic characteristics of <jats:italic>EPHA2<\/jats:italic> mutations in SSC and MPM reinstating the dynamics of different roles of <jats:italic>EPHA2<\/jats:italic> in cancer. This study also suggests that a combination of doxazosin and other EPHA2 inhibitors directed to inhibit the pertinent signaling components may be a novel therapeutic strategy for MPM and Non-small cell lung cancer patients who have either <jats:italic>EPHA2<\/jats:italic> or <jats:italic>CBL<\/jats:italic> alterations.<\/jats:p>","DOI":"10.1038\/s41389-019-0159-6","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T12:04:36Z","timestamp":1567598676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma"],"prefix":"10.1038","volume":"8","author":[{"given":"Yi-Hung Carol","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajani","family":"Kanteti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qudsia","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya N.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wickii T.","family":"Vigneswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Ming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarajan","family":"Vaidehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Mambetsariev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deric L.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"159_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccm.2011.08.005","volume":"32","author":"WD Travis","year":"2011","unstructured":"Travis, W. D. Pathology of lung cancer. Clin. Chest Med 32, 669\u2013692 (2011).","journal-title":"Clin. Chest Med"},{"key":"159_CR2","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.jtho.2016.11.087","volume":"12","author":"T Vavala","year":"2017","unstructured":"Vavala, T. & Novello, S. SC10.04 second-line therapy and beyond in squamous cell NSCLC. J. Thorac. Oncol. 12, S101\u2013S102 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"159_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3816\/CLC.2003.n.023","volume":"5","author":"PA Janne","year":"2003","unstructured":"Janne, P. A. Chemotherapy for malignant pleural mesothelioma. Clin. Lung Cancer 5, 98\u2013106 (2003).","journal-title":"Clin. Lung Cancer"},{"key":"159_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","volume":"117","author":"DJ Sugarbaker","year":"1999","unstructured":"Sugarbaker, D. J. et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc Surg. 117, 54\u201363 (1999).","journal-title":"J. Thorac. Cardiovasc Surg."},{"key":"159_CR5","first-page":"49","volume":"18","author":"HL Kindler","year":"2004","unstructured":"Kindler, H. L. The emerging role of pemetrexed for the treatment of malignant mesothelioma. Oncology (Williston Park) 18, 49\u201353 (2004).","journal-title":"Oncology (Williston Park)"},{"key":"159_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636\u20132644 (2003).","journal-title":"J. Clin. Oncol."},{"key":"159_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"P Blume-Jensen","year":"2001","unstructured":"Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355\u2013365 (2001).","journal-title":"Nature"},{"key":"159_CR8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nrm1662","volume":"6","author":"EB Pasquale","year":"2005","unstructured":"Pasquale, E. B. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 6, 462\u2013475 (2005).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"159_CR9","doi-asserted-by":"crossref","unstructured":"Locard-Paulet, M. et al. Phosphoproteomic analysis of tumor-endothelial signaling identifies EPHA2 as a negative regulator of transendothelial migration. Sci. Signal 9, ra15 (2016).","DOI":"10.1126\/scisignal.aac5820"},{"key":"159_CR10","doi-asserted-by":"crossref","unstructured":"Singh, D. R., Pasquale, E. B. & Hristova, K. A. Small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Biochim Biophys. Acta 9, 1922\u20131928 (2017).","DOI":"10.1016\/j.bbagen.2016.06.004"},{"key":"159_CR11","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1248\/bpb.b17-00446","volume":"10","author":"HSYue Zhou","year":"2017","unstructured":"Zhou, H. S. Yue Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression. Biol. Pharm. Bull. 10, 1616\u20131624 (2017).","journal-title":"Biol. Pharm. Bull."},{"key":"159_CR12","doi-asserted-by":"publisher","first-page":"18575","DOI":"10.1074\/jbc.M109.075085","volume":"285","author":"L Faoro","year":"2010","unstructured":"Faoro, L. et al. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J. Biol. Chem. 285, 18575\u201318585 (2010).","journal-title":"J. Biol. Chem."},{"key":"159_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0092-8674(01)00391-9","volume":"105","author":"D Schmucker","year":"2001","unstructured":"Schmucker, D. & Zipursky, S. L. Signaling downstream of Eph receptors and ephrin ligands. Cell 105, 701\u2013704 (2001).","journal-title":"Cell"},{"key":"159_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/35000008","volume":"2","author":"H Miao","year":"2000","unstructured":"Miao, H., Burnett, E., Kinch, M., Simon, E. & Wang, B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol. 2, 62\u201369 (2000).","journal-title":"Nat. Cell Biol."},{"key":"159_CR15","doi-asserted-by":"publisher","first-page":"16017","DOI":"10.1074\/jbc.M709934200","volume":"283","author":"WB Fang","year":"2008","unstructured":"Fang, W. B., Brantley-Sieders, D. M., Hwang, Y., Ham, A. J. & Chen, J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J. Biol. Chem. 283, 16017\u201316026 (2008).","journal-title":"J. Biol. Chem."},{"key":"159_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep10641","volume":"5","author":"BD Ferguson","year":"2015","unstructured":"Ferguson, B. D. et al. Novel EPHB4 receptor tyrosine kinase mutations and kinomic pathway analysis in lung cancer. Sci. Rep. 5, 10641 (2015).","journal-title":"Sci. Rep."},{"key":"159_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042120","volume":"7","author":"A Petty","year":"2012","unstructured":"Petty, A. et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS ONE 7, e42120 (2012).","journal-title":"PLoS ONE"},{"key":"159_CR18","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1038\/sj.onc.1207508","volume":"23","author":"P Chiarugi","year":"2004","unstructured":"Chiarugi, P. et al. LMW-PTP is a positive regulator of tumor onset and growth. Oncogene 23, 3905\u20133914 (2004).","journal-title":"Oncogene"},{"key":"159_CR19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0002-9440(10)63899-0","volume":"162","author":"J Walker-Daniels","year":"2003","unstructured":"Walker-Daniels, J., Hess, A. R., Hendrix, M. J. & Kinch, M. S. Differential regulation of EphA2 in normal and malignant cells. Am. J. Pathol. 162, 1037\u20131042 (2003).","journal-title":"Am. J. Pathol."},{"key":"159_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008972","volume":"5","author":"YH Tan","year":"2010","unstructured":"Tan, Y. H. et al. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS ONE 5, e8972 (2010).","journal-title":"PLoS ONE"},{"key":"159_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09078-4","volume":"7","author":"YC Tan","year":"2017","unstructured":"Tan, Y. C. et al. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci. Rep. 7, 9192 (2017).","journal-title":"Sci. Rep."},{"key":"159_CR22","first-page":"2414","volume":"22","author":"M Surati","year":"2011","unstructured":"Surati, M. et al. Generation of comprehensive thoracic oncology database-tool for translational research. J. Vis. Exp. 22, 2414 (2011).","journal-title":"J. Vis. Exp."},{"key":"159_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2043-9113-1-8","volume":"1","author":"M Surati","year":"2011","unstructured":"Surati, M. et al. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J. Clin. Bioinforma. 1, 1\u201311 (2011).","journal-title":"J. Clin. Bioinforma."},{"key":"159_CR24","doi-asserted-by":"publisher","first-page":"16156","DOI":"10.1073\/pnas.202610899","volume":"99","author":"TL Wang","year":"2002","unstructured":"Wang, T. L. et al. Digital karyotyping. Proc. Natl Acad. Sci. USA 99, 16156\u201316161 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"159_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."},{"key":"159_CR26","doi-asserted-by":"crossref","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aid. Mol. Des. 27, 221\u2013234 (2013).","DOI":"10.1007\/s10822-013-9644-8"},{"key":"159_CR27","doi-asserted-by":"crossref","unstructured":"Jacobson, M. P. et al. A. hierarchical approach to all-atom protein loop prediction. Proteins: Structure, Function and Bioinformatics. 55, 351\u2013367 (2004).","DOI":"10.1002\/prot.10613"},{"key":"159_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/ct700301q","volume":"4","author":"B Hess","year":"2008","unstructured":"Hess, B., Kutzner, C., van der Spoel, D. & Lindahl, E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4, 435\u2013447 (2008).","journal-title":"J. Chem. Theory Comput."},{"key":"159_CR29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","volume":"29","author":"S Pronk","year":"2013","unstructured":"Pronk, S. et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29, 845\u2013854 (2013).","journal-title":"Bioinformatics"},{"key":"159_CR30","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701\u20131718 (2005).","journal-title":"J. Comput. Chem."},{"key":"159_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0010-4655(95)00042-E","volume":"91","author":"HJC Berendsen","year":"1995","unstructured":"Berendsen, H. J. C. et al. GROMACS: a message-passing parallel molecular dynamics implementation. Comput. Phys. Commun. 91, 43\u201356 (1995).","journal-title":"Comput. Phys. Commun."},{"key":"159_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s008940100045","volume":"7","author":"E Lindahl","year":"2001","unstructured":"Lindahl, E., Hess, B. & van der Spoel, D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J. Mol. Model. 7, 306\u2013317 (2001).","journal-title":"J. Mol. Model."},{"key":"159_CR33","doi-asserted-by":"crossref","unstructured":"Evans, D. J. & Holians, B. L. The Nose\u2013Hoover thermostat. J. Chem. Phys. 83, 4069\u20134074 (1985).","DOI":"10.1063\/1.449071"},{"key":"159_CR34","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1103\/PhysRevLett.45.1196","volume":"45","author":"M Parrinello","year":"1980","unstructured":"Parrinello, M., Rahman, A. & Parrinello, M. R. A. Crystal structure and pair potentials: a molecular_dynamics study. Phys. Rev. Lett. 45, 1196\u20131199 (1980).","journal-title":"Phys. Rev. Lett."},{"key":"159_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD\u2014Visual Molecular Dynamics. J. Mol. Graph. 14, 33\u201338 (1996).","journal-title":"J. Mol. Graph."},{"key":"159_CR36","unstructured":"The PyMOL Molecular Graphics System, Version 1.3r1., (Schrodinger LLC., 2010)."},{"key":"159_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jmgm.2010.10.007","volume":"29","author":"JD Durrant","year":"2011","unstructured":"Durrant, J. D., de Oliveira, C. A. & McCammon, J. A. POVME: an algorithm for measuring binding-pocket volumes. J. Mol. Graph Model 29, 773\u2013776 (2011).","journal-title":"J. Mol. Graph Model"},{"key":"159_CR38","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1021\/ct500381c","volume":"10","author":"JD Durrant","year":"2014","unstructured":"Durrant, J. D., Votapka, L., Sorensen, J. & Amaro, R. E. POVME 2.0: \u0101n enhanced tool for determining pocket shape and volume characteristics. J. Chem. Theory Comput. 10, 5047\u20135056 (2014).","journal-title":"J. Chem. Theory Comput."},{"key":"159_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: a 2D graphics environment. Comput. Sci. Eng. 9, 90\u201395 (2007).","journal-title":"Comput. Sci. Eng."}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-019-0159-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-019-0159-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-019-0159-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T15:04:03Z","timestamp":1671203043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-019-0159-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1038\/s41389-019-0159-6","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"assertion":[{"value":"16 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"49"}}